Kamada Ltd. (NASDAQ: KMDA) is a leading international biopharmacy company that specializes in the development, production, and marketing of a wide range of plasma-derived protein therapeutics. Its operations are focused on orphan indications and immune and metabolic diseases. With headquarters in Rehovot, Israel, and commercialization across the globe, Kamada has continuously illustrated an unwavering commitment to addressing unmet patient needs and improving health outcomes.
Founded in 1990, the company has steadily grown to become an influential player in the global healthcare industry. Kamada takes a unique and innovative approach to its operations. By utilizing its proprietary platform technology, the company can deliver high-quality therapeutic proteins with improved pharmacokinetic, immunologic, and safety profiles.
The company operates via two segments – Proprietary Products, which develops, manufactures, and markets proprietary plasma-derived pharmaceuticals; and Distribution, which provides end-to-end solutions to international customers, including plasma collection, product development and registration, and more. Its flagship product is Glassia – the first-ever liquid, ready-to-use, intravenous plasma-derived AAT product approved by the US FDA.
Kamada’s product portfolio is known for its remarkable efficacy in treating a variety of conditions. Whether it’s an antitrypsin deficiency, which can lead to lung and liver diseases, or rabies, the company's range of plasma-derived protein therapeutics addresses an extensive array of health problems. Kamada is also a primary supplier of specialty plasma-derived hyperimmunoglobulins and various biological entities for biotherapy shortages.
As a company that hinges on strong partnerships, Kamada has strategic alliances with a variety of pharmaceutical industry leaders, including Takeda, Covance, Baxter, and Chiesi Farmaceutici.
In recent years, Kamada has also shown a commitment to environmental, social, and governance (ESG) factors, recognizing that significant impact on human health begins with sustainable and ethical business practices. The company is dedicated to reducing its environmental footprint, investing in its employees, contributing to society, and maintaining the highest standards of corporate governance.
Through a rich pipeline and consistent investment in research and development, Kamada maintains its position as a leading global-specialty plasma-focused bio-pharmaceutical company. It's commitment to enhancing patient healthcare systems worldwide while maintaining a responsibility toward a sustainable future truly sets Kamada Ltd. apart in the international healthcare industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Amir London, CEO of Kamada (NASDAQ: KMDA), acquired stock options for 800,000 shares on September 25, allowing him to purchase the stock at $6.71 per share. The transaction, valued at approximately $1.80 million based on the current stock price of $8.96, signals a positive outlook from the insider. The article also provides an analysis of Kamada's financial health, including revenue growth, profitability metrics, debt management, and valuation.
Lilach Payorski, a Director at Kamada (NASDAQ: KMDA), acquired stock options for 60,000 shares valued at $136,577. This transaction, disclosed on September 24, allows her to purchase shares at an exercise price of $6.69 each. The article also provides a detailed financial overview of Kamada, highlighting its revenue growth, profitability, debt management, and market valuation.
Boris Gorelik, VP at Kamada (NASDAQ: KMDA), exercised stock options for 0 shares of KMDA, resulting in a transaction value of $0, as disclosed in an SEC filing on September 24. This occurred while Kamada shares were down 0.91% and trading at $8.96. The article also provides a financial overview of Kamada, highlighting its revenue growth, gross margin, EPS, debt management, and valuation metrics.
KAMADA LTD (NASDAQ: KMDA), a biotechnology company, awarded 86,500 derivative securities to director Goldwasser Karnit on August 27, 2026, at a price of $0 per share. Following these three transactions, which were reported under SEC transaction code A, Goldwasser Karnit's post-transaction holding of derivative securities is 30,000. The article highlights the distinction between the awarded amount and the director's total derivative security ownership.
Assaf Itshayek, a Director at Kamada (NASDAQ: KMDA), acquired 46,000 stock options with an exercise price of $6.93 per share, valued at $80,739. This insider transaction highlights a positive sentiment towards the company. Kamada, a plasma-derived protein therapeutics company, reported a 22.72% revenue growth but faces challenges with a low gross margin and high debt-to-equity ratio.
Kamada's CFO, Chaime Orlev, acquired 202,500 company stock options valued at $413,774, according to a recent SEC filing. The options allow Orlev to purchase shares at $6.65 each, indicating confidence in the Health Care sector company. The article also provides a financial overview of Kamada, detailing its revenue growth, gross margin, EPS, debt management, and various valuation ratios.
Nir Livneh, VP at Kamada (NASDAQ: KMDA), recently acquired stock options for 89,485 shares, valued at $171,121 based on current trading prices. Kamada is a drug-focused company specializing in plasma-derived protein therapeutics, reporting a 22.72% revenue growth but facing challenges with a low gross margin and high debt-to-equity ratio. The article highlights the importance of insider transactions as an indicator of positive expectations, while also discussing Kamada's financial metrics and valuation.
Leon Recanati, a Board Member at Kamada (NASDAQ: KMDA), recently acquired stock options for 86,500 shares, valued at $154,219, with an exercise price of $6.91 per share. This strategic move was disclosed in a September 23 SEC filing. The article also provides a financial overview of Kamada, highlighting its revenue growth, gross margin, EPS, debt management, and valuation metrics, while emphasizing the importance of insider transactions as indicators of future stock performance.
Eran Nir, VP at Kamada (NASDAQ: KMDA), has acquired stock options for 112,500 shares, valued at $173,474. The options allow him to buy shares at an exercise price of $7.15 per share, indicating a strategic derivative acquisition. Kamada, a plasma-derived protein therapeutics company, shows strong revenue growth but faces challenges in gross margin, debt management, and higher-than-average valuation ratios.